Introduction and Objective: Early stage T1D screening programs in routine clinical care are in their infancy. With the availability of teplizumab, a disease-modifying therapy that delays progression to Stage 3 T1D, there is an urgent need to reimagine T1D care. Understanding current screening practices can inform implementation strategies and identify gaps as the field moves toward early detection and intervention.Methods: A cross-sectional survey was administered to 64 centers participating in the T1DX-QI Collaborative; the survey was open from August to October 2025. Survey responses were analyzed using descriptive statistics to characterize current screening practices, autoantibody testing approaches, and readiness for teplizumab administration.Results: Responses were received from 63 centers (98% response rate). Among respondents, 67% were pediatric centers and 33% were adult centers. Survey results are displayed in Table 1.Conclusion: T1D screening programs are emerging but remain more common in pediatric than adult centers. Although many sites report initiation of screening activities, autoantibody testing is frequently conducted through research-based platforms with variable integration into routine clinical workflows, highlighting the opportunity for standardized approaches to early detection and intervention in clinical care.
D.J. DeSalvo: Consultant; Current; Dexcom, Inc., Insulet Corporation. Advisory Panel; Current; Sanofi. Research Support; Current; Medtronic. A. Tuttle: Other – Scientific Education Program Moderator; Ended; Sanofi. E.L. Ospelt: None. T. Wright: None. C. Demeterco-Berggren: Advisory Panel; Ended; Sanofi. Board Member; Current; Glooko, Inc. Research Support; Ended; Medtronic. L.E. Culbreth: None. S. Majidi: Advisory Panel; Current; Sanofi. C. Rainey: None. L. Jacobsen: Consultant; Current; Sanofi.
The Leona M. and Harry B. Helmsley Charitable Trust
Source link
Leave a Reply